A novel UPLC-MS/MS based method to determine the activity of N-acetylglutamate synthase in liver tissue
- PMID: 27771289
- DOI: 10.1016/j.ymgme.2016.10.004
A novel UPLC-MS/MS based method to determine the activity of N-acetylglutamate synthase in liver tissue
Abstract
Background: N-acetylglutamate synthase (NAGS) plays a key role in the removal of ammonia via the urea cycle by catalyzing the synthesis of N-acetylglutamate (NAG), the obligatory cofactor in the carbamyl phosphate synthetase 1 reaction. Enzymatic analysis of NAGS in liver homogenates has remained insensitive and inaccurate, which prompted the development of a novel method.
Methods: UPLC-MS/MS was used in conjunction with stable isotope (N-acetylglutamic-2,3,3,4,4-d5 acid) dilution for the quantitative detection of NAG produced by the NAGS enzyme. The assay conditions were optimized using purified human NAGS and the optimized enzyme conditions were used to measure the activity in mouse liver homogenates.
Results: A low signal-to-noise ratio in liver tissue samples was observed due to non-enzymatic formation of N-acetylglutamate and low specific activity, which interfered with quantitative analysis. Quenching of acetyl-CoA immediately after the incubation circumvented this analytical difficulty and allowed accurate and sensitive determination of mammalian NAGS activity. The specificity of the assay was validated by demonstrating a complete deficiency of NAGS in liver homogenates from Nags -/- mice.
Conclusion: The novel NAGS enzyme assay reported herein can be used for the diagnosis of inherited NAGS deficiency and may also be of value in the study of secondary hyperammonemia present in various inborn errors of metabolism as well as drug treatment.
Keywords: Hyperammonia; Mass spectrometry; N-acetylglutamate; NAGS-deficiency.
Copyright © 2016. Published by Elsevier Inc.
Similar articles
-
Gene delivery corrects N-acetylglutamate synthase deficiency and enables insights in the physiological impact of L-arginine activation of N-acetylglutamate synthase.Sci Rep. 2021 Feb 11;11(1):3580. doi: 10.1038/s41598-021-82994-8. Sci Rep. 2021. PMID: 33574402 Free PMC article.
-
Use of pure recombinant human enzymes to assess the disease-causing potential of missense mutations in urea cycle disorders, applied to N-acetylglutamate synthase deficiency.J Inherit Metab Dis. 2024 Nov;47(6):1194-1212. doi: 10.1002/jimd.12747. Epub 2024 May 13. J Inherit Metab Dis. 2024. PMID: 38740568 Free PMC article.
-
Presentation and management of N-acetylglutamate synthase deficiency: a review of the literature.Orphanet J Rare Dis. 2020 Oct 9;15(1):279. doi: 10.1186/s13023-020-01560-z. Orphanet J Rare Dis. 2020. PMID: 33036647 Free PMC article.
-
Noncoding sequence variants define a novel regulatory element in the first intron of the N-acetylglutamate synthase gene.Hum Mutat. 2021 Dec;42(12):1624-1636. doi: 10.1002/humu.24281. Epub 2021 Sep 24. Hum Mutat. 2021. PMID: 34510628 Free PMC article.
-
N-acetylglutamate synthase: structure, function and defects.Mol Genet Metab. 2010;100 Suppl 1(Suppl 1):S13-9. doi: 10.1016/j.ymgme.2010.02.018. Epub 2010 Feb 26. Mol Genet Metab. 2010. PMID: 20303810 Free PMC article. Review.
Cited by
-
Systematic multi-level analysis of an organelle proteome reveals new peroxisomal functions.Mol Syst Biol. 2022 Sep;18(9):e11186. doi: 10.15252/msb.202211186. Mol Syst Biol. 2022. PMID: 36164978 Free PMC article.
-
Bupleurum marginatum Wall.ex DC in Liver Fibrosis: Pharmacological Evaluation, Differential Proteomics, and Network Pharmacology.Front Pharmacol. 2018 May 17;9:524. doi: 10.3389/fphar.2018.00524. eCollection 2018. Front Pharmacol. 2018. PMID: 29867514 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases